immunocompromised-tickets- 55714561754.

Early registration is recommended because seating is limited; therefore, FDA may limit the number of participants from each organization. Registrants will receive confirmation when they have been accepted. If time and space permit, onsite registration on the day of the public workshop will be provided beginning at 7:30 a.m. We will let registrants know if registration closes before the day of the public workshop.

If you need special accommodations due to a disability, please contact Jessica Barnes or Lori Benner (see FOR FURTHER INFORMATION CONTACT) no later than August 1, 2019.

Requests for Oral Presentations: During online registration you may indicate if you wish to present during a public comment session or participate in a specific session, and which topic(s) you wish to address. We will do our best to accommodate requests to make public comments. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and request time for a joint presentation, or submit requests for designated representatives to participate in the focused sessions. Following the close of registration, we will determine the amount of time allotted to each presenter and the approximate time each oral presentation is to begin, and will select and notify participants by August 2, 2019. All requests to make oral presentations must be received by the close of registration on July 29, 2019. If selected for presentation, any presentation materials must be emailed to ONDPublicMTGSupport@fda.hhs.gov no later than August 5, 2019. No commercial or promotional material will be permitted to be presented or distributed at the public workshop.

Streaming Webcast of the Public Workshop: This public workshop will also be webcast at the following site: https://collaboration.fda.gov/ oapdavp080819.

If you have never attended a Connect Pro event before, test your connection at https://collaboration.fda.gov/common/ help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro program, visit https://www.adobe.com/ go/connectpro_overview. FDA has verified the website addresses in this document, as of the date this document publishes in the **Federal Register**, but websites are subject to change over time.

Transcripts: Please be advised that as soon as a transcript of the public workshop is available, it will be accessible at https:// www.regulations.gov. It may be viewed at the Dockets Management Staff (see ADDRESSES). A link to the transcript will also be available on the internet at https://www.fda.gov/Drugs/NewsEvents/ ucm630653.htm.

Dated: April 29, 2019.

Lowell J. Schiller,

Principal Associate Commissioner for Policy. [FR Doc. 2019–08993 Filed 5–1–19; 8:45 am] BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-0001]

Preparation for International Cooperation on Cosmetics Regulation Thirteenth Annual Meeting; Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting.

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "International **Cooperation on Cosmetics Regulation** (ICCR)—Preparation for ICCR-13 Meeting." The purpose of the public meeting is to invite public input on various topics pertaining to the regulation of cosmetics. We may use this input to help us prepare for the ICCR-13 meeting that will be held July 9 to 11, 2019, in Montreal, Canada. **DATES:** The public meeting will be held on June 5, 2019, from 2 p.m. to 4 p.m. See the SUPPLEMENTARY INFORMATION section for registration date and information.

ADDRESSES: The public meeting will be held at the Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Dr., Wiley Auditorium (first floor), College Park, MD 20740.

FOR FURTHER INFORMATION CONTACT: Jonathan Hicks, Office of Cosmetics and Colors, Food and Drug Administration, 5001 Campus Dr. (HFS–125), College Park, MD 20740, 240–402–1375, Jonathan.Hicks@fda.hhs.gov. SUPPLEMENTARY INFORMATION:

I. Background

The intention of the ICCR multilateral framework is to pave the way for the removal of regulatory obstacles to international trade while maintaining global consumer protection. The purpose of the meeting is to invite public input on various topics pertaining to the regulation of cosmetics. We may use this input to help us prepare for the ICCR–13 meeting that will be held July 9 to 11, 2019, in Montreal, Canada.

ICCR is a voluntary international group of cosmetics regulatory authorities from Brazil, Canada, the European Union, Japan, and the United States of America. These regulatory authority members will engage in constructive dialogue with their relevant cosmetics industry trade associations and public advocacy groups. Currently, the ICCR members are: The Brazilian Health Surveillance Agency; Health Canada; the European Commission Directorate-General for Internal Market, Industry, Entrepreneurship, and Small and Medium-sized Enterprises; the Ministry of Health, Labor, and Welfare of Japan; and FDA. All decisions are made by consensus and will be compatible with the laws, policies, rules, regulations, and directives of the respective administrations and governments. Members will implement and/or promote actions or documents within their own jurisdictions and seek convergence of regulatory policies and practices. Successful implementation will need input from stakeholders.

II. Topics for Discussion at the Public Meeting

We will make the agenda for the public meeting available on the internet at *https://www.fda.gov/Cosmetics/ InternationalActivities/ICCR/ default.htm.* Depending on the number of requests for oral presentations, we intend to have an agenda available by May 29, 2019.

III. Participating in the Public Meeting

Registration: To register for the public meeting, send registration information (including your name, title, affiliation, address, email, and telephone), to Jonathan Hicks by May 22, 2019. If you would like to listen to the meeting by phone, please submit a request for a dial-in number by May 22, 2019 (see **FOR FURTHER INFORMATION CONTACT**). If you need special accommodations due to a disability, please contact Jonathan Hicks by May 29, 2019.

Requests for Oral Presentations: If you wish to present, you should notify Jonathan Hicks by May 22, 2019, and submit a brief statement of the general nature of the presentation: What you wish to present, your name, title, affiliation, address, email, and telephone, and indicate the approximate amount of time needed to make your presentation. You may wish to present proposals for future ICCR agenda items, data, information, or views, in person or in writing, on issues pending at the

public meeting or a topic related to a previous meeting. There will be no presentations by phone. Time allotted for oral presentations may be limited to 10 minutes or less for each presenter, depending on the number of requests received.

Transcripts: Please be advised that as soon as a transcript of the public meeting is available, it will be accessible at *https://www.regulations.gov.* It may also be viewed at the Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20850.

Dated: April 26, 2019.

Lowell J. Schiller,

Principal Associate Commissioner for Policy. [FR Doc. 2019–08897 Filed 5–1–19; 8:45 am] BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Notice of a HRSA-Initiated Supplemental Award to Recipients in the Reaching Practicing Maternal and Child Health (MCH) Professionals in Underserved Areas Through Education and Training Program

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). **ACTION:** Notice of a HRSA-Initiated Supplemental Award to Recipients in the Reaching Practicing Maternal and Child Health (MCH) Professionals in Underserved Areas through Education and Training Program.

SUMMARY: HRSA announces the award of a supplement of \$705,246 for the **Reaching Practicing MCH Professionals** in Underserved Areas through Education and Training Program (hereafter Program) recipients. The supplement will allow the current four recipients, during the period of June 1, 2019-May 31, 2020, to continue supporting the development and implementation of in-depth training tailored to the specific needs of MCH public health professionals practicing in underserved communities, including rural and frontier areas and Indian reservations.

SUPPLEMENTARY INFORMATION:

Intended Recipients of Award: The Regents of the University of Colorado, The University of Texas Health Science Center at Houston, University of New Mexico, and University of Washington.

Amount of Non-Competitive Awards: \$705,246. Period of Supplemental Funding: 06/

Period of Supplemental Funding: 06/ 01/2019–05/31/2020.

CFDA Number: 93.110.

Authority: Social Security Act, Title V, § 501(a)(2) (42 U.S.C. 701(a)(2)).

Justification: The purpose of the Program is to strengthen the nation's (59 states and jurisdictions) public health system by developing the MCH public health workforce in underserved and geographically isolated communities, including rural, frontier areas, and Indian reservations. The purpose of the supplement from HRSA is to extend the performance period of the current four recipients to continue supporting the development and implementation of indepth training tailored to the specific needs of MCH public health professionals practicing in underserved communities. These four recipients received their original awards for the period of June 1, 2014 through May 31, 2019 through a competitive process. The non-competitive supplement will allow grantees to complete training activities consistent with approved activities in their competing applications. Activities will include outreach and training for MCH professionals in tribal communities and training for MCH professionals on pressing topics such as mental health and substance use disorders. This supports the overall goal of the Program to strengthen the nation's public health system by developing the MCH public health workforce in underserved and geographically isolated communities.

FOR FURTHER INFORMATION CONTACT:

Samantha Croffut, Division of Maternal and Child Health Workforce Development, Maternal and Child Health Bureau, HRSA, 5600 Fishers Lane, Room 18W62, Rockville, MD 20852, Phone: 301–443–3139, Email: *SCroffut@hrsa.gov.*

Grantee/organization name	Grant No.	State	FY 2018 authorized funding level	FY 2019 proposed funding level
The Regents of the University of Colorado The University of Texas Health Science Center at Houston University of New Mexico University of Washington	T04MC26890 T04MC12785 T04MC26891 T04MC26892	NM	\$176,634 \$176,138	Up to \$175,866. Up to \$176,634. Up to \$176,138. Up to \$176,608.

Dated: April 26, 2019.

George Sigounas,

Administrator. [FR Doc. 2019–08877 Filed 5–1–19; 8:45 am] BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Notice of a HRSA-Initiated Supplemental Award to the University of Nebraska Medical Center/Board of Regents of the University of Nebraska for the Partnership for Urban Maternal and Child Health (MCH) Leadership Community Cooperative Agreement

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice of a HRSA-Initiated Supplemental Award to the University of Nebraska Medical Center/Board of Regents of the University of Nebraska for the Partnership for Urban Maternal and Child Health (MCH) Leadership Community Cooperative Agreement.

SUMMARY: HRSA announces the award of a supplement for \$700,000 to the University of Nebraska Medical Center/ Board of Regents of the University of Nebraska for the Partnership for Urban MCH Leadership Community Cooperative Agreement. The supplement will allow the current recipient, during the period of May 1, 2019–April 30, 2020, to assess the outcomes and impact of its collective impact learning collaborative with urban health departments.